This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1905)
- Annex to CHMP highlights(367)
- Annual Report(91)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(121)
- EPAR - All authorised presentations(1976)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2704)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(140)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Full risk management plan(0)
- EPAR - Overview(1972)
- EPAR - Paediatric investigation plan compliance statement(88)
- EPAR - Procedural steps taken and scientific information after authorisation(1880)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1972)
- EPAR - Public assessment report(1547)
- EPAR - Risk-management-plan summary(1137)
- EPAR - Scientific conclusion(1353)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(246)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(163)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(71)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(803)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(22)
- Minutes(1249)
- Newsletter(298)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4058)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2759)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5475)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5305)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2769)
- Regulatory and procedural guideline(722)
- Report(1619)
- Scientific guideline(2464)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1223)
- Summary of opinion - Initial authorisation(1672)
- Supply shortage(58)
- Template or form(479)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- Advanced therapies(1796)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(649)
- Brexit(121)
- Careers(5)
- Clinical trials(587)
- Compassionate use(16)
- Compliance and inspections(600)
- Corporate(113)
- COVID-19(898)
- Data on medicines(989)
- Early access(201)
- Fees(24)
- Generic and hybrid medicines(2180)
- Governance(708)
- Innovation(1164)
- Maximum residue limit(1001)
- Medication error(28)
- Medicines(46965)
- Medicines for use outside the EU(148)
- Medicine shortages(298)
- Mpox(39)
- Paediatrics(12235)
- Parallel distribution(15)
- Pharmacovigilance(9555)
- Procurement(132)
- Product information(6321)
- Quality of medicines(222)
- Rare diseases(8243)
- Referrals(3384)
- Regulatory and procedural guidance(3518)
- Research and development(494)
- Scientific advice(289)
- Scientific guidelines(1739)
- SME(259)
- Vaccines(1500)
- Veterinary limited markets(64)
Search results (84300)
Ryzodeg : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (227.83 KB - PDF)
Zepatier : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (140.83 KB - PDF)
Minimum inhibitory concentration (MIC) breakpoints
English (EN) (365.34 KB - XLSX)
EMA recommends refusal of authorisation for Ibuprofen NVT (ibuprofen, 400 mg, soft capsules)
English (EN) (109.62 KB - PDF)
Zepatier : EPAR - Product information
English (EN) (460.1 KB - PDF)
български (BG) (443.88 KB - PDF)
español (ES) (484.08 KB - PDF)
čeština (CS) (507.01 KB - PDF)
dansk (DA) (476.9 KB - PDF)
Deutsch (DE) (508.82 KB - PDF)
eesti keel (ET) (456.04 KB - PDF)
ελληνικά (EL) (448.02 KB - PDF)
français (FR) (532.41 KB - PDF)
hrvatski (HR) (507.94 KB - PDF)
íslenska (IS) (449.72 KB - PDF)
italiano (IT) (485.45 KB - PDF)
latviešu valoda (LV) (450.52 KB - PDF)
lietuvių kalba (LT) (462.18 KB - PDF)
magyar (HU) (539.04 KB - PDF)
Malti (MT) (651.88 KB - PDF)
Nederlands (NL) (463.16 KB - PDF)
norsk (NO) (455.58 KB - PDF)
polski (PL) (553.01 KB - PDF)
português (PT) (477.92 KB - PDF)
română (RO) (473.79 KB - PDF)
slovenčina (SK) (510.13 KB - PDF)
slovenščina (SL) (484.48 KB - PDF)
Suomi (FI) (482.76 KB - PDF)
svenska (SV) (452.97 KB - PDF)